NetraMark ads

A negative Phase 3 result does not necessarily mean a treatment lacks biological or clinical effect. In a new Clinical Trial Vanguard interview, Luca Pani, MD, explains how treatment-effect heterogeneity can dilute meaningful signals, and why adding more patients may not address a poorly chosen population. Learn how NetraAI analyzes existing trial data to identify interpretable patient subpopulations most likely to benefit from a selected treatment.

Evaluating clinical trials using population averages can dilute the signals of patients who respond very differently. Analyzing only a sponsor’s trial data, NetraAI identifies clinically meaningful response structure and discovers interpretable combinations of patient characteristics that define differentiated treatment response groups. Unlike standard methods, NetraAI separates noise from signal and delivers explainable insights that sponsors can prospectively test in future trials.

In clinical trials, clinical, molecular, imaging, and behavioral patient data are often collected and stored across disparate systems. NetraAI simultaneously analyzes all collected patient data to identify response patterns across subpopulations that can help inform clinical development decisions. Designed to work alongside existing scientific and statistical workflows, NetraAI provides transparent, explainable evidence that helps sponsors understand not only what happened across populations in their trial, but also why.

Promising treatment signals can be hidden by conventional analyses. When patients with very different response profiles are grouped into one population average, meaningful effects can become harder to identify. NetraAI analyzes a sponsor’s existing clinical trial data to identify patient-level response structure and the clinical variable combinations that define different subgroups. Purpose-built for smaller, complex clinical datasets, NetraAI helps development teams understand who responded, who didn’t, and what may be driving the difference.